Jazz Pharmaceuticals (JAZZ) Common Equity (2010 - 2026)

Jazz Pharmaceuticals' Common Equity history runs 17 years deep, the most recent figure standing at $4.5 billion for Q1 2026.

• On a quarterly basis, Common Equity rose 8.56% year-over-year to $4.5 billion in Q1 2026; TTM through Mar 2026 was $4.5 billion, a 8.56% increase from a year earlier, with the FY2025 full-year figure at $4.3 billion, up 5.49% from the prior year.
• Common Equity improved to $4.5 billion in Q1 2026 per JAZZ's latest filing, from $4.3 billion in the prior quarter.
• Across five years, Common Equity topped out at $4.5 billion in Q1 2026 and bottomed at $2.7 billion in Q3 2022.
• The 5-year median for Common Equity is $3.7 billion (2025), against an average of $3.7 billion.
• Across the five-year window, Common Equity plunged 30.3% in 2022 and increased 27.11% in 2023, its largest moves.
• Year by year, Common Equity stood at $3.1 billion in 2022, then climbed by 21.11% to $3.7 billion in 2023, then climbed by 9.55% to $4.1 billion in 2024, then increased by 5.49% to $4.3 billion in 2025, then advanced by 4.95% to $4.5 billion in 2026.
• Per Business Quant, the three latest JAZZ Common Equity figures stand at $4.5 billion (Q1 2026), $4.3 billion (Q4 2025), and $4.0 billion (Q3 2025).